With BurstDR, very few patients have any sensation that the device is operating other than the fact that they're getting relief and that they look at their controller and they see ‘Oh, it's operating.’ They don't really feel it because it's outside of what we call the ‘sensory range’ in terms of its electrical parameters. With most older types of neurostimulation, the patient felt a “buzzy,” tingling feeling that sort of replaces the painful areas, which in some people is terrific and other people could be a little bit bothersome because they felt it operating. This interview has been edited for length and clarity.Īllen Burton: One differentiating characteristic is that the patient doesn't feel it operating. Prior to joining Abbott in 2015, Burton was chairman of the department of pain medicine at the University of Texas MD Anderson Cancer Center for eleven years. Medtech Insight talked to Allen Burton, the divisional vice president and chief medical officer of Abbott’s neuromodulation business, to learn more about Abbott’s specific approach to SCS and how it expects to bring the therapy to more people with chronic pain.Īs an experienced pain medicine physician, Burton has published more than 50 peer-reviewed articles and co-authored textbooks on managing pain in cancer patients and assessing movement skills. The FDA also recently expanded the magnetic resonance imaging labeling for Abbott’s Eterna SCS, allowing a wider selection of MRI-compatible leads. The average improvement in pain scores was about 70%. Also, 91.4% of subjects treated with SCS therapy reported either significant pain relief or significantly improved function. In the trial, more than 85% of the patients implanted with an Abbott SCS device reported a significant reduction in back pain compared to only 7.1% in the conservative medical management arm. Allen Burton, CMO of Abbott’s Neuromodulation Business Abbott The approval is based on the results of the 270-patient randomized DISTINCT trial, which is the largest randomized controlled trial of SCS in people with non-surgical back pain, according to Abbott.ĭr. (Also see " Nevro Attacks Pain And Competition With Individualized AI-Enabled Spinal Cord Stimulator" - Medtech Insight, 6 Apr, 2023.) Proclaim and Eterna deliver BurstDR, the company's proprietary low-energy stimulation waveform.Ībbott’s SCS devices will compete directly with Nevro’s Senza HFX devices, which earned FDA approval for the non-surgical back pain indication in January 2022. The new labeling covers all of Abbott's SCS devices sold in the US, including recharge-free Proclaim SCS devices and the rechargeable Eterna SCS platform. (Also see " Minute Insight: FDA Approves Abbott’s SCS For Non-Surgical Back Pain" - Medtech Insight, 16 May, 2023.) In May, the US Food and Drug Administration approved a new indication for Abbott’s spinal cord stimulation (SCS) devices that includes people with chronic back pain that cannot be treated with surgery. Abbott is bringing its spinal cord stimulation (SCS) technology to chronic back pain sufferers who currently have no clear treatment path.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |